Users online: 1613    [ij] [ij] [ij] 
Email id

International Journal of Drug Regulatory Affairs (IJDRA)
Year : 2018, Volume : 6, Issue : 3
First page : ( 24) Last page : ( 30)
Print ISSN : 2321-2162. Online ISSN : 2321-6794.
Article DOI : 10.22270/ijdra.v6i3.264

Saxagliptin and Dapagliflozin for type 2 Diabetes mellitus: A Review

Ranjan Deepshi1,*, Sharma Akanksha2, Bodla Ramesh Babu2

1Department of Quality Assurance, DIPSAR, Sector 3, Puspvihar, New Delhi, India

2Department of Pharmaceutical Chemistry, DIPSAR, Sector 3, Puspvihar, New Delhi, India

*Corresponding author Tel.: +91-8506909848; E-mail address: deepshi.ranjan7@gmail.com (Deepshi Ranjan)

Online published on 17 September, 2019.


Qtern® is a fixed dose combination tablet of Saxagliptin and Dapagliflozin which is indicated for the advancement of glycaemic control in adults with type 2 diabetes mellitus (T2DM). It can be done either when medication with metformin and/or a sulfonylurea with a monocomponent of either Saxagliptin or Dapagliflozin render poor glycaemic control, or when the subject is treated with the free combination of Saxagliptin and Dapagliflozin. This review compiles pathophysiology of type 2 diabetes mellitus (T2DM) along with pharmacological properties, mechanism of action, and side effects of both the drugs. Furthermore, the method of determination of combination is described in this review. The agents have corresponding mechanisms of action, which further adds to the benefit of using this combination. The mixture is associated with reduced body weight and a low risk of hypoglycaemia. It is the first dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose cotransporter (SGLT2) inhibitor fixed-dose combination available in the EU therefore can act as potent option for glycaemic control in patients with T2DM.



Qtern, Saxagliptin, Dapagliflozin, Type 2 diabetes mellitus, Pharmacokinetics, Pharmacodynamics.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
519,451,270 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.